SCHEMBL2400136

SCHEMBL2400136

Fc1ccc(CC(F)c2nnc(-c3ccc4[nH]cnc4c3)o2)cc1

nearest known ligand 0.52

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
QPCT Q16769 19/20 0.52
PSMD11 O00231 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2395930 0.78 QPCT (0.52) QPCT
SCHEMBL2394839 0.77 QPCT (0.51) QPCT
SCHEMBL1706601 0.77 QPCT (0.84) QPCT
SCHEMBL1706008 0.77 QPCT (0.84) QPCT
SCHEMBL2397364 0.76 QPCTL (0.44) QPCT
SCHEMBL2397650 0.75 QPCT (0.45) QPCT
SCHEMBL1706156 0.73 QPCT (0.83) QPCTPSMD11
SCHEMBL2397400 0.71 QPCT (0.46) QPCT
SCHEMBL20587550 0.70 QPCT (0.44) QPCT
SCHEMBL29673268 0.70 QPCT (0.44) QPCT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181233-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-11-10 US disclosed
US-20110224259-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224259-A1 NOVEL INHIBITORS QPCT, GLUL, GLS QPCT 1/4885PSMD11 2414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.